{"id":"NCT01652729","sponsor":"AstraZeneca","briefTitle":"Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus","officialTitle":"A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02","primaryCompletion":"2014-04","completion":"2014-04","firstPosted":"2012-07-30","resultsPosted":"2015-04-23","lastUpdate":"2015-08-20"},"enrollment":365,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Type 2"],"interventions":[{"type":"DRUG","name":"Exenatide once weekly suspension","otherNames":[]},{"type":"DRUG","name":"Sitagliptin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Exenatide once weekly suspension","type":"EXPERIMENTAL"},{"label":"Sitagliptin 100mg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by sitagliptin or placebo administered once daily for 28 weeks in subjects with type 2 diabetes mellitus.","primaryOutcome":{"measure":"Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28","timeFrame":"Baseline to Week 28","effectByArm":[{"arm":"Experimental: Exenatide","deltaMin":-1.13,"sd":0.1093},{"arm":"Active Comparator: Sitagliptin","deltaMin":-0.75,"sd":0.1324},{"arm":"Placebo Comparator: Placebo","deltaMin":-0.4,"sd":0.1945}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0010"},{"comp":"OG000 vs OG001","p":"0.0209"},{"comp":"OG001 vs OG002","p":"0.1347"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":60,"countries":["United States"]},"refs":{"pmids":["32306296","28205322"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2733&filename=BCB120_Synopsis.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":181},"commonTop":["Nausea","Injection Site Nodule","Nasopharyngitis"]}}